Full Press Release Details
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024
VICTORIA, BRITISH COLUMBIA (CANADA), October 21, 2024 ImmunoPrecise Antibodies Ltd. (the Company or IPA ) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that Dr. Dirk Van Hyfte, Head of Innovation at BioStrand, IPA's AI subsidiary, will participate on a Fireside Chat during the AI Driven Drug Discovery Summit USA 2024 taking place at the Aloft Boston Seaport District Hotel, Boston, Massachusetts, November 12-14, 2024.
AI Driven Drug Discovery Summit
Date: Thursday, November 14
Format: Fireside Chat
To register for the event, please click here
For appointment scheduling, please contact Jennifer K. Zimmons, PhD, MBA, at Quantum Media: jen@quantum-corp.com , +1.917.214.3514.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family ).
Investor Relations Contact
Quantum Media Group, LLC
Source: ImmunoPrecise Antibodies Ltd.